Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.

Bielekova, B et al.·Nature medicine·2000·
RPEP-005802000RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.
Published In:
Nature medicine, 6(10), 1167-75 (2000)
Database ID:
RPEP-00580

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-00580·https://rethinkpeptides.com/research/RPEP-00580

APA

Bielekova, B; Goodwin, B; Richert, N; Cortese, I; Kondo, T; Afshar, G; Gran, B; Eaton, J; Antel, J; Frank, J A; McFarland, H F; Martin, R. (2000). Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.. Nature medicine, 6(10), 1167-75.

MLA

Bielekova, B, et al. "Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.." Nature medicine, 2000.

RethinkPeptides

RethinkPeptides Research Database. "Encephalitogenic potential of the myelin basic protein pepti..." RPEP-00580. Retrieved from https://rethinkpeptides.com/research/bielekova-2000-encephalitogenic-potential-of-the

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.